Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Receivables Change in Receivables Change in Taxes Change in Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Net Cash Flow Net Cash Flow Net Income Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Ratios

Keros Therapeutics (KROS) Change in Taxes (2025)

Keros Therapeutics filings provide 1 years of Change in Taxes readings, the most recent being -$1.9 million for Q4 2025.

On a quarterly basis, Change in Taxes changed N/A to -$1.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $2.2 million, a N/A change, with the full-year FY2025 number at $2.2 million, changed N/A from a year prior.
Change in Taxes hit -$1.9 million in Q4 2025 for Keros Therapeutics, up from -$2.2 million in the prior quarter.
In the past five years, Change in Taxes ranged from a high of $10.0 million in Q1 2025 to a low of -$3.7 million in Q2 2025.